STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia
Authors:
- Marjolaine DebantMDMarjolaine Debant
- Miguel BurgosMBMiguel Burgos
- Patrice HemonPHPatrice Hemon
- Paul BuscagliaPBPaul Buscaglia
- Tinhinane FaliTFTinhinane Fali
- Sarra MelayahSMSarra Melayah
- Nelig Le GouxNGNelig Le Goux
- Christophe VandierCVChristophe Vandier
- Marie Potier-CartereauMPMarie Potier-Cartereau
- Jacques-Olivier PersJPJacques-Olivier Pers
- Adrian TempesculATAdrian Tempescul
- Christian BerthouCBChristian Berthou
Open Access
- 23 April 2019
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 7 (1) , 111
Abstract
Background Dysregulation in calcium (Ca2+) signaling is a hallmark of chronic lymphocytic leukemia (CLL). While the role of the B cell receptor (BCR) Ca2+ pathway has been associated with disease progression, the importance of the newly described constitutive Ca2+ entry (CE) pathway is less clear. In addition, we hypothesized that these differences reflect modifications of the CE pathway and Ca2+ actors such as Orai1, transient receptor potential canonical (TRPC) 1, and stromal interaction molecule 1 (STIM1), the latter being the focus of this study. Methods An extensive analysis of the Ca2+ entry (CE) pathway in CLL B cells was performed including constitutive Ca2+ entry, basal Ca2+ levels, and store operated Ca2+ entry (SOCE) activated following B cell receptor engagement or using Thapsigargin. The molecular characterization of the calcium channels Orai1 and TRPC1 and to their partner STIM1 was performed by flow cytometry and/or Western blotting. Specific siRNAs for Orai1, TRPC1 and STIM1 plus the Orai1 channel blocker Synta66 were used. CLL B cell viability was tested in the presence of an anti-STIM1 monoclonal antibody (mAb, clone GOK) coupled or not with an anti-CD20 mAb, rituximab. The Cox regression model was used to determine the optimal threshold and to stratify patients. Results Seeking to explore the CE pathway, we found in untreated CLL patients that an abnormal CE pathway was (i) highly associated with the disease outcome; (ii) positively correlated with basal Ca2+ concentrations; (iii) independent from the BCR-PLCγ2-InsP3R (SOCE) Ca2+ signaling pathway; (iv) supported by Orai1 and TRPC1 channels; (v) regulated by the pool of STIM1 located in the plasma membrane (STIM1PM); and (vi) blocked when using a mAb targeting STIM1PM. Next, we further established an association between an elevated expression of STIM1PM and clinical outcome. In addition, combining an anti-STIM1 mAb with rituximab significantly reduced in vitro CLL B cell viability within the high STIM1PM CLL subgroup. Conclusions These data establish the critical role of a newly discovered BCR independent Ca2+ entry in CLL evolution, provide new insights into CLL pathophysiology, and support innovative therapeutic perspectives such as targeting STIM1 located at the plasma membrane.Keywords
Funding Information
- Ligue Contre le Cancer
This publication has 35 references indexed in Scilit:
- Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatmentAmerican Journal of Hematology, 2017
- Molecular Dynamics Simulations of Membrane-Bound STIM1 to Investigate Conformational Changes during STIM1 Activation upon Calcium ReleaseJournal of Chemical Information and Modeling, 2017
- Role of Calcium Signaling in B Cell Activation and Biology2015
- STIM1, a direct target of microRNA-185, promotes tumor metastasis and is associated with poor prognosis in colorectal cancerOncogene, 2014
- Pivotal Role of the Lipid Raft SK3–Orai1 Complex in Human Cancer Cell Migration and Bone MetastasesCancer Research, 2013
- Store-operated Ca2+ entry is sensitive to the extracellular Ca2+ concentration through plasma membrane STIM1Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2009
- Calcium signalling in lymphocyte activation and diseaseNature Reviews Immunology, 2007
- Stromal interaction molecule 1 (STIM1), a transmembrane protein with growth suppressor activity, contains an extracellular SAM domain modified by N-linked glycosylationBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 2002
- STIM1: a novel phosphoprotein located at the cell surfaceBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 2000
- GOK: a gene at 11p15 involved in rhabdomyosarcoma and rhabdoid tumor development.1997